Patient 2 had no deletion of CDKN2A or CDKN2B, a wildtype of ATRX and TP53 gene, and exhibited well differentiated glioma without anaplasia, leading to a CNS WHO grade 2. This evidence concerns the gene CDKN2A and central nervous system cancer.